Antibodies for HIV prevention: the path forward

The lack of accountability in defining a timely pathway for equitable access to and scale-up of medical innovations has led to scepticism among key constituencies about the value of investing and participating in HIV prevention research. Communities are tired of promises of improved prevention options that do not materialize for those most in need.

Read more here.